This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Antibiotics

Updated on 16/01/2019

ANTIBIOTICS

Supporting global Antimicrobial Resistance (AMR) Awareness and Surveillance1

MSD is implementing a holistic approach to combating infectious disease

To improve global surveillance and drive awareness of AMR, MSD is committed to:

* The SMART program is one of the world's largest programs for tracking trends in AMR, monitoring in vitro susceptibility patterns of clinical Gram-negative bacilli to 12 commonly-used antibiotics. Over 200,000 isolates have been collected since its launch.

Advancing Antimicrobial Stewardship (AMS)

“The rise in infections that are resistant to current antibiotics has become one of the world’s most pressing public health problems. We are proud to reaffirm our longstanding commitment to develop new therapeutics to fight infectious diseases, and to continue to collaborate with others to support antimicrobial stewardship to help slow the rate of emerging resistance.”
Dr. Julie Gerberding, Executive Vice President and Chief Patient Officer

To promote AMS, MSD commits to:

For 125 years, MSD has been engaged in the fight against infectious disease, including the production of penicillin during World War II

Prescribing information for all mentioned products can be found below.

Supporting documentation

POM = Prescription only Medicine

CANCIDAS (Caspofungin)
Prescribing Information
Summary of Product Characteristics

CUBICIN 350 mg (Daptomycin)
POM 1 pack powder for injection x £62.00
Summary of Product Characteristics

CUBICIN 500 mg (Daptomycin)
POM 1 pack powder for injection x £88.57
Summary of Product Characteristics

DIFICLIR (Fidaxomicin)
Licensed by Astellas Pharma Ltd in Europe
POM £1350.00 (BNF Online Accessed 13 March 2018)
Summary of Product Characteristics

GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant)
Prescribing Information
Summary of Product Characteristics

GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
Prescribing Information
Summary of Product Characteristics

HBVAXPRO (Hepatitis B Vaccine, Recombinant)
Prescribing Information
Summary of Product Characteristics

INVANZ (Ertapenem)
POM 1 vial x £31.65
Summary of Product Characteristics

ISENTRESS (Raltegravir)
Prescribing Information
Summary of Product Characteristics

MMRvaxPro (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
Prescribing Information
Summary of Product Characteristics

NOXAFIL (Posaconazole)
Prescribing Information
Summary of Product Characteristics

PNEUMOCOCCAL POLYSACCHARIDE VACCINE (Pneumococcal Vaccine Polyvalent)
Prescribing Information
Summary of Product Characteristics

PRIMAXIN (Imipenem and Cilastatin)
POM 1 x 500 mg/20ml vial £12.00
Summary of Product Characteristics

SIVEXTRO 200 mg powder for injection (Tedizolid phosphate)
POM 1 x 6 vials £862.00
Summary of Product Characteristics

SIVEXTRO 200 mg tablets (Tedizolid phosphate)
POM 1 x 6 tablets £862.00
Summary of Product Characteristics

VARIVAX (Varicella Virus Vaccine Live)
Prescribing Information
Summary of Product Characteristics

VAQTA Adult (Hepatitis A vaccine, inactivated)
Prescribing Information
Summary of Product Characteristics

VAQTA Paediatric (Hepatitis A vaccine, inactivated)
Prescribing Information
Summary of Product Characteristics

ZERBAXA (Ceftolozane/tazobactam)
Prescribing Information
Summary of Product Characteristics

ZOSTAVAX (Zoster Vaccine Live)
Prescribing Information
Summary of Product Characteristics

References

  1. MSD's work in antimicrobial resistance http://www.msd.com/about/our-work/amr.html (Accessed July 2018).
  2. Study for Monitoring Antimicrobial Resistance Trends (SMART) http://partnerships.ifpma.org/partnership/study-for-monitoring-antimicrobial-resistance-trends-smart IFPMA Health Partnerships Directory (Accessed July 2018).
  3. British Society for Antimicrobial Chemotherapy (BSAC) Resistance Surveillance Project http://www.bsacsurv.org/ (Accessed July 2018).

GB-ZER-00022 | Date of Preparation: January 2019